Ribomic Inc. (TYO:4591)

Japan · Delayed Price · Currency is JPY

87.00

+3.00 (3.57%)

Aug 27, 2026, 2:40 PM JST

-21.62% (1Y)

Market Cap	4.75B +4.4%
Revenue (ttm)	7.50M +650.0%
Net Income	-1.19B
EPS	-22.69
Shares Out	56.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	664,400
Open	84.00
Previous Close	84.00
Day's Range	84.00 - 88.00
52-Week Range	57.00 - 120.00
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Ribomic

Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glauco... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2003

Employees 25

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4591

Full Company Profile

Financial Performance

In fiscal year 2026, Ribomic's revenue was 3.00 million, an increase of 50.00% compared to the previous year's 2.00 million. Losses were -1.15 billion, 12.5% more than in 2025.

Financial Statements